Next Article in Journal
VitalSign6: A Primary Care First (PCP-First) Model for Universal Screening and Measurement-Based Care for Depression
Next Article in Special Issue
Iron Supplementation Therapy, A Friend and Foe of Mycobacterial Infections?
Previous Article in Journal
Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases
Previous Article in Special Issue
The Importance of Iron Status for Young Children in Low- and Middle-Income Countries: A Narrative Review

Deregulation of Hepatic Mek1/2–Erk1/2 Signaling Module in Iron Overload Conditions

Institute of Comparative Molecular Endocrinology, University of Ulm, Ulm 89081, Germany
Department of Medicine III and IZKF, University Hospital Aachen, Aachen 52074, Germany
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Pharmaceuticals 2019, 12(2), 70;
Received: 25 February 2019 / Revised: 30 April 2019 / Accepted: 5 May 2019 / Published: 7 May 2019
(This article belongs to the Special Issue Iron as Therapeutic Targets in Human Diseases)
The liver, through the production of iron hormone hepcidin, controls body iron levels. High liver iron levels and deregulated hepcidin expression are commonly observed in many liver diseases including highly prevalent genetic iron overload disorders. In spite of a number of breakthrough investigations into the signals that control hepcidin expression, little progress has been made towards investigations into intracellular signaling in the liver under excess of iron. This study examined hepatic signaling pathways underlying acquired and genetic iron overload conditions. Our data demonstrate that hepatic iron overload associates with a decline in the activation of mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (Erk) kinase (Mek1/2) pathway by selectively affecting the phosphorylation of Erk1/2. We propose that Mek1/2-Erk1/2 signaling is uncoupled from iron-Bmp-Smad-mediated hepcidin induction and that it may contribute to a number of liver pathologies in addition to toxic effects of iron. We believe that our findings will advance the understanding of cellular signaling events in the liver during iron overload of different etiologies. View Full-Text
Keywords: liver; iron; hepcidin; Mek/Erk; Hfe; Bmp/Smad liver; iron; hepcidin; Mek/Erk; Hfe; Bmp/Smad
Show Figures

Figure 1

MDPI and ACS Style

Tangudu, N.K.; Buth, N.; Strnad, P.; Cirstea, I.C.; Spasić, M.V. Deregulation of Hepatic Mek1/2–Erk1/2 Signaling Module in Iron Overload Conditions. Pharmaceuticals 2019, 12, 70.

AMA Style

Tangudu NK, Buth N, Strnad P, Cirstea IC, Spasić MV. Deregulation of Hepatic Mek1/2–Erk1/2 Signaling Module in Iron Overload Conditions. Pharmaceuticals. 2019; 12(2):70.

Chicago/Turabian Style

Tangudu, Naveen K., Nils Buth, Pavel Strnad, Ion C. Cirstea, and Maja V. Spasić 2019. "Deregulation of Hepatic Mek1/2–Erk1/2 Signaling Module in Iron Overload Conditions" Pharmaceuticals 12, no. 2: 70.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop